POTENTIAL ADVERSE EFFECTS OF ORAL ANTIDIABETIC DRUGS IN OUTPATIENTS AT PUSKESMAS CILONGOK 1 BANYUMAS

Heny Ekowati; Shuntia Maslaha; Eva Dania Kosasih; Esti Dyah Utami; Nuryanti Nuryanti

doi:10.20884/2.procicma.2025.1.1.20259

Heny Ekowati Pharmacy Department, Faculty of Health Sciences, Universitas Jenderal Soedirman, Purwokerto, 53123, Central Java, Indonesia
Shuntia Maslaha Pharmacy Department, Faculty of Health Sciences, Universitas Jenderal Soedirman, Purwokerto, 53123, Central Java, Indonesia
Eva Dania Kosasih Pharmacy Department, Faculty of Health Sciences, Universitas Jenderal Soedirman, Purwokerto, 53123, Central Java, Indonesia
Esti Dyah Utami Pharmacy Department, Faculty of Health Sciences, Universitas Jenderal Soedirman, Purwokerto, 53123, Central Java, Indonesia
Nuryanti Nuryanti Pharmacy Department, Faculty of Health Sciences, Universitas Jenderal Soedirman, Purwokerto, 53123, Central Java, Indonesia

DOI: https://doi.org/10.20884/2.procicma.2025.1.1.20259

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease that requires long-term therapy. The use of oral antidiabetic drugs needs to be evaluated to minimize the risk of adverse effects. Cilongok 1 Public Health Center has the highest number of patients with T2DM in Banyumas Regency. The aim of this study was to evaluate the potential ADE profile of oral antidiabetic drugs in outpatients at Cilongok 1 Community Health Center. This study was a prospective descriptive study conducted over two months, employing purposive sampling. Data were collected through medical records, patient medication history, and interviews using a structured questionnaire. Analysis of adverse effects was conducted based on patient interviews and categorized by organ system. A total of 72 patients were analyzed, with the majority receiving combination therapy (69.44%). Metformin was the most frequently used drug, either as monotherapy or in combination. Potential adverse effects were found in 59.72% of patients, with the most frequent complaints involving the nervous system, gastrointestinal system, and metabolic system. The use of oral antidiabetic drugs in T2DM patients was dominated by combination therapy, particularly metformin and glimepiride. Potential adverse effects were identified in more than half of patients, with the nervous system most frequently affected.